Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study.

@article{Liebowitz2020EfficacyIA,
  title={Efficacy, immunogenicity, and safety of an oral influenza vaccine: a placebo-controlled and active-controlled phase 2 human challenge study.},
  author={David N. Liebowitz and Keith A. Gottlieb and Nikita S. Kolhatkar and Shaily J. Garg and Jason Asher and John Nazareno and Kenneth Kim and David R McIIwain and Sean N. Tucker},
  journal={The Lancet. Infectious diseases},
  year={2020}
}

Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection

It is demonstrated that, compared to expression of the S1 domain or a stabilized spike antigen, the full length, wild-type spike antigen induces significantly higher neutralizing antibodies in the periphery and in the lungs, when the vaccine is administered mucosally.

Influenza vaccines: Past, present, and future

The history of influenza vaccine development, the immune responses induced by the vaccines and the adjuvants applied are described, and future directions for improving the effectiveness of influenza vaccines in all age groups are suggested.

Influenza vaccines: where we are, where we are going

Various strategies are discussed, including using more stable influenza antigens such as the hemagglutinin stalk and internal proteins as well as new adjuvants, new vaccine formulations, and DNA/RNA-based vaccines that are currently being developed.

Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response

This review highlights the current progress and advances in the development of RIVs in the context of heterosubtypic immunity induction toward universal vaccine production, and discussed existing knowledge on influenza and vaccine development, current hemagglutinin-based RIV's in the market and in the pipeline, other potential vaccine targets for RIVS, and deantigenization process.

Therapeutic Advances in Vaccines and Immunotherapy

The traditional manufacturing process for influenza vaccines relies on fertilized chicken eggs that are used for vaccine production, but adoption of cell-culture technology for influenza vaccine manufacturing has been reported to improve manufacturing efficiency and the additional benefit of improving vaccine effectiveness is a key factor for future policy making considerations.

Viral vector-based vaccines against SARS-CoV-2

Adenovirus vector-based vaccines are the most advanced with several vaccines receiving Emergency Use Authorization (EUA) and vaccine candidates based on vaccinia virus and lentivirus vectors have been subjected to clinical evaluation.
...

References

SHOWING 1-10 OF 18 REFERENCES

Response to a monovalent 2009 influenza A (H1N1) vaccine.

A single 15-microg dose of 2009 H1N1 vaccine was immunogenic in adults, with mild-to-moderate vaccine-associated reactions.

Nasal IgA Provides Protection against Human Influenza Challenge in Volunteers with Low Serum Influenza Antibody Titre

IgA contributes to protection against influenza and should be targeted in vaccines, and the length of time infectious virus was recovered from the nose was reduced in patients with higher pre-existing H1N1 influenza specific nasal IgA or serum IgA.

The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses

SUMMARY The intranasal inoculation of volunteers with living partially attenuated strains of influenza A and B viruses offers a new opportunity to determine the protective effect of serum

Characterisation of a wild-type influenza (A/H1N1) virus strain as an experimental challenge agent in humans

A highly characterised wild-type Influenza A/California/2009 (H1N1) virus manufactured for clinical use was shown to induce a good infectivity profile in human volunteers and can be used for evaluating potential efficacy of vaccines and anti-viral therapeutics.

Human Circulating Antibody-Producing B Cell as a Predictive Measure of Mucosal Immunity to Poliovirus

The results suggest that virus-specific blood ASCs, especially for type 3 poliovirus, can serve as surrogate of mucosal immunity after vaccination, and whole blood-based mucosal ASC testing for polio eradication is suggested.

Systemic and mucosal immune responses following oral adenoviral delivery of influenza vaccine to the human intestine by radio controlled capsule

Both intestinal sites were capable of inducing mucosal and systemic immune responses to influenza hemagglutinin, but ileum delivery induced higher numbers of antibody secreting cells of IgG and IgA isotypes, increased mucosal homing B cells, and higher number of vaccine responders.